Italy's largest drug maker A. Menarini IFR hopes to penetrate the US market via the in-licensing of drugs in therapeutic areas such as oncology and cardiovascular, and perhaps by making an acquisition there, the group's corporate licensing director Giammario Piras says in a television interview, adding that entering Japan might prove harder to do but is nonetheless a priority. The group is also expanding its over-the-counter offerings in Asia.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?